Lh (Menotropins)

CHEMBL1201697 Phase 4 Aprovado Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This preparation of luteinizing hormone (LH) derived from the urine of postmenopausal women is used in fertility treatments to stimulate ovulation in women who do not ovulate naturally. LH works together with follicle-stimulating hormone (FSH) to trigger the final maturation and release of eggs.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This preparation of luteinizing hormone (LH) derived from the urine of postmenopausal women is used in fertility treatments to stimulate ovulation in women who do not ovulate naturally. LH works together with follicle-stimulating hormone (FSH) to trigger the final maturation and release of eggs.

Yes, Lh (Menotropins) is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201697. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Procura informações acessíveis para o paciente?

Lh (Menotropins) no PillFYI

Dados Rápidos

Links Externos

ChEMBL CHEMBL1201697

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.